Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A global initiative to deliver precision health in diabetes.
Cefalu WT, Franks PW, Rosenblum ND, Zaghloul NA, Florez JC, Giorgino F, Ji L, Ma RCW, Mathieu C, Misra S, Ramirez AH, Roden M, Scherer PE, Sheu WH, Stehouwer CDA, Woo M, Pragnell M, Anand SS, Carnethon M, Chambers JC, Dennis JM, Gloyn AL, Herder C, Holt RIG, Manuel DG, Redondo MJ, Tandon N, Tsang JS, Udler MS, Rich SS. Cefalu WT, et al. Among authors: ma rcw. Nat Med. 2024 Jul;30(7):1819-1822. doi: 10.1038/s41591-024-03032-4. Nat Med. 2024. PMID: 38992126 No abstract available.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Scirica BM, et al. N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2. N Engl J Med. 2013. PMID: 23992601 Free article. Clinical Trial.
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators. Steg PG, et al. N Engl J Med. 2019 Oct 3;381(14):1309-1320. doi: 10.1056/NEJMoa1908077. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475798 Free article. Clinical Trial.
Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.
Jiang G, Luk AOY, Tam CHT, Xie F, Carstensen B, Lau ESH, Lim CKP, Lee HM, Ng ACW, Ng MCY, Ozaki R, Kong APS, Chow CC, Yang X, Lan HY, Tsui SKW, Fan X, Szeto CC, So WY, Chan JCN, Ma RCW; Hong Kong Diabetes Register TRS Study Group. Jiang G, et al. Among authors: ma rcw. Kidney Int. 2019 Jan;95(1):178-187. doi: 10.1016/j.kint.2018.08.026. Epub 2018 Nov 8. Kidney Int. 2019. PMID: 30415941 Free article.
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
Mu Y, Bao X, Eliaschewitz FG, Hansen MR, Kim BT, Koroleva A, Ma RCW, Yang T, Zu N, Liu M; STEP 7 Study Group. Mu Y, et al. Among authors: ma rcw. Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. doi: 10.1016/S2213-8587(23)00388-1. Epub 2024 Feb 5. Lancet Diabetes Endocrinol. 2024. PMID: 38330988 Clinical Trial.
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators. Bhatt DL, et al. Lancet. 2019 Sep 28;394(10204):1169-1180. doi: 10.1016/S0140-6736(19)31887-2. Epub 2019 Sep 1. Lancet. 2019. PMID: 31484629 Free article. Clinical Trial.
Type 2 diabetes pathway-specific polygenic risk scores elucidate heterogeneity in clinical presentation, disease progression and diabetic complications in 18,217 Chinese individuals with type 2 diabetes.
Yu G, Tam CHT, Lim CKP, Shi M, Lau ESH, Ozaki R, Lee HM, Ng ACW, Hou Y, Fan B, Huang C, Wu H, Yang A, Cheung HM, Lee KF, Siu SC, Hui G, Tsang CC, Lau KP, Leung JYY, Cheung EYN, Tsang MW, Kam G, Lau IT, Li JKY, Yeung VTF, Lau E, Lo S, Fung S, Cheng YL, Szeto CC; Hong Kong Diabetes Biobank Study Group; Chow E, Kong APS, Tam WH, Luk AOY, Weedon MN, So WY, Chan JCN, Oram RA, Ma RCW; TRANSCEND Consortium. Yu G, et al. Among authors: ma rcw. Diabetologia. 2024 Nov 12. doi: 10.1007/s00125-024-06309-y. Online ahead of print. Diabetologia. 2024. PMID: 39531041
430 results